These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 25804644)

  • 1. Uncovering the clinical utility of miR-143, miR-145 and miR-224 for predicting the survival of bladder cancer patients following treatment.
    Avgeris M; Mavridis K; Tokas T; Stravodimos K; Fragoulis EG; Scorilas A
    Carcinogenesis; 2015 May; 36(5):528-37. PubMed ID: 25804644
    [TBL] [Abstract][Full Text] [Related]  

  • 2. microRNA expression profile in a large series of bladder tumors: identification of a 3-miRNA signature associated with aggressiveness of muscle-invasive bladder cancer.
    Pignot G; Cizeron-Clairac G; Vacher S; Susini A; Tozlu S; Vieillefond A; Zerbib M; Lidereau R; Debre B; Amsellem-Ouazana D; Bieche I
    Int J Cancer; 2013 Jun; 132(11):2479-91. PubMed ID: 23169479
    [TBL] [Abstract][Full Text] [Related]  

  • 3. miR-221/222 cluster expression improves clinical stratification of non-muscle invasive bladder cancer (TaT1) patients' risk for short-term relapse and progression.
    Tsikrika FD; Avgeris M; Levis PK; Tokas T; Stravodimos K; Scorilas A
    Genes Chromosomes Cancer; 2018 Mar; 57(3):150-161. PubMed ID: 29181884
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circulating miR-205: a promising biomarker for the detection and prognosis evaluation of bladder cancer.
    Fang Z; Dai W; Wang X; Chen W; Shen C; Ye G; Li L
    Tumour Biol; 2016 Jun; 37(6):8075-82. PubMed ID: 26715266
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased BCL2L12 expression predicts the short-term relapse of patients with TaT1 bladder cancer following transurethral resection of bladder tumors.
    Foutadakis S; Avgeris M; Tokas T; Stravodimos K; Scorilas A
    Urol Oncol; 2014 Jan; 32(1):39.e29-36. PubMed ID: 23790536
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Downregulated KLK13 expression in bladder cancer highlights tumor aggressiveness and unfavorable patients' prognosis.
    Tokas T; Avgeris M; Alamanis C; Scorilas A; Stravodimos KG; Constantinides CA
    J Cancer Res Clin Oncol; 2017 Mar; 143(3):521-532. PubMed ID: 27858162
    [TBL] [Abstract][Full Text] [Related]  

  • 7. miR-143, miR-222, and miR-452 are useful as tumor stratification and noninvasive diagnostic biomarkers for bladder cancer.
    Puerta-Gil P; García-Baquero R; Jia AY; Ocaña S; Alvarez-Múgica M; Alvarez-Ossorio JL; Cordon-Cardo C; Cava F; Sánchez-Carbayo M
    Am J Pathol; 2012 May; 180(5):1808-15. PubMed ID: 22426337
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MicroRNA expression profiles in muscle-invasive bladder cancer: identification of a four-microRNA signature associated with patient survival.
    Xu Z; Yu YQ; Ge YZ; Zhu JG; Zhu M; Zhao YC; Xu LW; Yang XB; Geng LG; Dou QL; Jia RP
    Tumour Biol; 2015 Sep; 36(10):8159-66. PubMed ID: 25990459
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical implications and prognostic values of topoisomerase-II alpha expression in primary non-muscle-invasive bladder cancer.
    Kim EJ; Lee YS; Kim YJ; Kim MJ; Ha YS; Jeong P; Lee OJ; Kim WJ
    Urology; 2010 Jun; 75(6):1516.e9-13. PubMed ID: 19913893
    [TBL] [Abstract][Full Text] [Related]  

  • 10. miRNA profiling identifies candidate mirnas for bladder cancer diagnosis and clinical outcome.
    Ratert N; Meyer HA; Jung M; Lioudmer P; Mollenkopf HJ; Wagner I; Miller K; Kilic E; Erbersdobler A; Weikert S; Jung K
    J Mol Diagn; 2013 Sep; 15(5):695-705. PubMed ID: 23945108
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ki-67 is an independent indicator in non-muscle invasive bladder cancer (NMIBC); combination of EORTC risk scores and Ki-67 expression could improve the risk stratification of NMIBC.
    Ding W; Gou Y; Sun C; Xia G; Wang H; Chen Z; Tan J; Xu K; Qiang D
    Urol Oncol; 2014 Jan; 32(1):42.e13-9. PubMed ID: 24360660
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased expression of miR-222 is associated with poor prognosis in bladder cancer.
    Zhang DQ; Zhou CK; Jiang XW; Chen J; Shi BK
    World J Surg Oncol; 2014 Jul; 12():241. PubMed ID: 25078265
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pattern of somatostatin receptors expression in normal and bladder cancer tissue samples.
    Karavitakis M; Msaouel P; Michalopoulos V; Koutsilieris M
    Anticancer Res; 2014 Jun; 34(6):2937-42. PubMed ID: 24922657
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RUNX3 methylation as a predictor for disease progression in patients with non-muscle-invasive bladder cancer.
    Yan C; Kim YW; Ha YS; Kim IY; Kim YJ; Yun SJ; Moon SK; Bae SC; Kim WJ
    J Surg Oncol; 2012 Mar; 105(4):425-30. PubMed ID: 22311819
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Direct quantitative detection for cell-free miR-155 in urine: a potential role in diagnosis and prognosis for non-muscle invasive bladder cancer.
    Zhang X; Zhang Y; Liu X; Fang A; Wang J; Yang Y; Wang L; Du L; Wang C
    Oncotarget; 2016 Jan; 7(3):3255-66. PubMed ID: 26657502
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of miR-100 and miR-138 as prognostic biomarkers in non-muscle-invasive bladder cancer.
    Blanca A; Sanchez-Gonzalez A; Requena MJ; Carrasco-Valiente J; Gomez-Gomez E; Cheng L; Cimadamore A; Montironi R; Lopez-Beltran A
    APMIS; 2019 Aug; 127(8):545-553. PubMed ID: 31231851
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MicroRNA-155 promotes bladder cancer growth by repressing the tumor suppressor DMTF1.
    Peng Y; Dong W; Lin TX; Zhong GZ; Liao B; Wang B; Gu P; Huang L; Xie Y; Lu FD; Chen X; Xie WB; He W; Wu SX; Huang J
    Oncotarget; 2015 Jun; 6(18):16043-58. PubMed ID: 25965824
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of cell cycle-associated proteins in non-muscle-invasive bladder cancer: correlation with intravesical recurrence following transurethral resection.
    Behnsawy HM; Miyake H; Abdalla MA; Sayed MA; Ahmed Ael-F; Fujisawa M
    Urol Oncol; 2011; 29(5):495-501. PubMed ID: 19914103
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EORTC progression score identifies patients at high risk of cancer-specific mortality after radical cystectomy for secondary muscle-invasive bladder cancer.
    May M; Burger M; Brookman-May S; Stief CG; Fritsche HM; Roigas J; Zacharias M; Bader M; Mandel P; Gilfrich C; Seitz M; Tilki D
    Clin Genitourin Cancer; 2014 Aug; 12(4):278-86. PubMed ID: 24331576
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Decreased expression of microRNA-31 associates with aggressive tumor progression and poor prognosis in patients with bladder cancer.
    Wang S; Li Q; Wang K; Dai Y; Yang J; Xue S; Han F; Zhang Q; Liu J; Wu W
    Clin Transl Oncol; 2013 Oct; 15(10):849-54. PubMed ID: 23408039
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.